(EL) EssilorLuxottica S. A. - Ratings and Ratios
Lenses, Frames, Sunglasses, Equipment, Instruments
Dividends
| Dividend Yield | 1.31% |
| Yield on Cost 5y | 3.38% |
| Yield CAGR 5y | 36.14% |
| Payout Consistency | 92.1% |
| Payout Ratio | 76.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 20.9% |
| Value at Risk 5%th | 32.6% |
| Relative Tail Risk | -5.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.01 |
| Alpha | 29.08 |
| CAGR/Max DD | 1.10 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.411 |
| Beta | 0.224 |
| Beta Downside | 0.300 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.26% |
| Mean DD | 5.11% |
| Median DD | 3.66% |
Description: EL EssilorLuxottica S. A. December 02, 2025
EssilorLuxottica S.A. (EL) designs, manufactures, and distributes a full spectrum of ophthalmic products-including lenses, frames, sunglasses, and contact lenses-across North America, Europe, Asia-Pacific, the Middle East, Africa, and Latin America. Its portfolio spans premium brands such as Ray-Ban, Oakley, Varilux, Crizal, and Transitions, as well as professional-grade equipment and digital imaging platforms (e.g., SPECTRALIS, ANTERION, HEYEX) for eye-care practitioners.
The company also supplies optometry tools, lens-edging instruments, and consumables under the Satisloh brand, serving independent opticians, large retail chains, e-commerce platforms, and end-consumers through an extensive brick-and-mortar and online network. This vertically integrated model links vision assessment, prescription fulfillment, and after-sales services.
Key economic drivers for EL include the global aging population (projected to increase the prevalence of presbyopia by ~30 % by 2030), rising digital-screen usage fueling demand for blue-light-filtering lenses, and expanding middle-class consumption in emerging markets such as India and Brazil. In FY 2023, EL reported €24.5 bn in revenue, a 5.2 % year-over-year increase, and a market-share of roughly 15 % in the global eyewear segment.
Investors should note that EL’s earnings per share (EPS) grew 8 % YoY to €9.10, while its operating margin improved to 13.5 % after cost-saving initiatives in the supply chain. The firm’s exposure to both consumer discretionary (eyewear fashion) and healthcare (vision correction) makes it relatively resilient to macro-economic swings, though currency fluctuations in the euro-dollar pair remain a material risk.
For a deeper quantitative assessment, the ValueRay platform offers a granular breakdown of EL’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (4.67b TTM) > 0 and > 6% of Revenue (6% = 3.18b TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 4.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.68% (prev -1.91%; Δ 1.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 9.73b > Net Income 4.67b (YES >=105%, WARN >=100%) |
| Net Debt (11.26b) to EBITDA (13.11b) ratio: 0.86 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.97 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (462.0m) change vs 12m ago 2.85% (target <= -2.0% for YES) |
| Gross Margin 62.67% (prev 63.78%; Δ -1.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 86.90% (prev 72.18%; Δ 14.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.62 (EBITDA TTM 13.11b / Interest Expense TTM 420.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.15
| (A) -0.01 = (Total Current Assets 11.03b - Total Current Liabilities 11.39b) / Total Assets 61.93b |
| (B) 0.25 = Retained Earnings (Balance) 15.53b / Total Assets 61.93b |
| (C) 0.11 = EBIT TTM 6.98b / Avg Total Assets 61.08b |
| (D) 0.57 = Book Value of Equity 13.52b / Total Liabilities 23.52b |
| Total Rating: 2.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.98
| 1. Piotroski 6.0pt |
| 2. FCF Yield 4.14% |
| 3. FCF Margin 12.63% |
| 4. Debt/Equity 0.37 |
| 5. Debt/Ebitda 0.86 |
| 6. ROIC - WACC (= 4.69)% |
| 7. RoE 12.02% |
| 8. Rev. Trend 62.23% |
| 9. EPS Trend -3.10% |
What is the price of EL shares?
Over the past week, the price has changed by -1.98%, over one month by -4.33%, over three months by +16.56% and over the past year by +33.79%.
Is EL a buy, sell or hold?
What are the forecasts/targets for the EL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 312.3 | 3.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 373 | 23.3% |
EL Fundamental Data Overview November 29, 2025
Market Cap EUR = 148.13b (148.13b EUR * 1.0 EUR.EUR)
P/E Trailing = 61.9961
P/E Forward = 38.1679
P/S = 5.3219
P/B = 3.833
P/EG = 2.9464
Beta = 0.72
Revenue TTM = 53.08b EUR
EBIT TTM = 6.98b EUR
EBITDA TTM = 13.11b EUR
Long Term Debt = 6.81b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.68b EUR (from shortTermDebt, last quarter)
Debt = 14.05b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.26b EUR (from netDebt column, last quarter)
Enterprise Value = 161.93b EUR (148.13b + Debt 14.05b - CCE 246.0m)
Interest Coverage Ratio = 16.62 (Ebit TTM 6.98b / Interest Expense TTM 420.0m)
FCF Yield = 4.14% (FCF TTM 6.70b / Enterprise Value 161.93b)
FCF Margin = 12.63% (FCF TTM 6.70b / Revenue TTM 53.08b)
Net Margin = 8.80% (Net Income TTM 4.67b / Revenue TTM 53.08b)
Gross Margin = 62.67% ((Revenue TTM 53.08b - Cost of Revenue TTM 19.81b) / Revenue TTM)
Gross Margin QoQ = 63.05% (prev 61.79%)
Tobins Q-Ratio = 2.61 (Enterprise Value 161.93b / Total Assets 61.93b)
Interest Expense / Debt = 1.05% (Interest Expense 147.0m / Debt 14.05b)
Taxrate = 24.16% (463.0m / 1.92b)
NOPAT = 5.29b (EBIT 6.98b * (1 - 24.16%))
Current Ratio = 0.97 (Total Current Assets 11.03b / Total Current Liabilities 11.39b)
Debt / Equity = 0.37 (Debt 14.05b / totalStockholderEquity, last quarter 37.82b)
Debt / EBITDA = 0.86 (Net Debt 11.26b / EBITDA 13.11b)
Debt / FCF = 1.68 (Net Debt 11.26b / FCF TTM 6.70b)
Total Stockholder Equity = 38.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.55% (Net Income 4.67b / Total Assets 61.93b)
RoE = 12.02% (Net Income TTM 4.67b / Total Stockholder Equity 38.87b)
RoCE = 15.28% (EBIT 6.98b / Capital Employed (Equity 38.87b + L.T.Debt 6.81b))
RoIC = 11.00% (NOPAT 5.29b / Invested Capital 48.11b)
WACC = 6.32% (E(148.13b)/V(162.18b) * Re(6.84%) + D(14.05b)/V(162.18b) * Rd(1.05%) * (1-Tc(0.24)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.97%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈5.56b ; Y1≈6.85b ; Y5≈11.69b
Fair Price DCF = 429.5 (DCF Value 198.87b / Shares Outstanding 463.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -3.10 | EPS CAGR: -55.60% | SUE: 0.0 | # QB: 0
Revenue Correlation: 62.23 | Revenue CAGR: 21.55% | SUE: 1.16 | # QB: 1
EPS next Year (2026-12-31): EPS=7.96 | Chg30d=+0.140 | Revisions Net=+14 | Growth EPS=+11.6% | Growth Revenue=+7.5%